Dr. Tina Xiang is a patent agent in the New York office of Wilson Sonsini Goodrich & Rosati. She has experience in the fields of cancer biology, targeted therapy, genetics, and cellular and molecular biology. Tina applies her experience to patent prosecution, freedom-to-operate, and due diligence matters for clients in the life sciences, pharmaceutical, biotechnology, diagnostics, and medical devices industries.
Prior to joining the firm, Tina completed her doctorate degree at Columbia University. Her dissertation focused on the development of subtype-specific targeted therapy for Muscle-Invasive Bladder Cancer. While at Columbia, Tina was also a fellow at Columbia Technology Ventures, the university’s technology transfer office.
Tina is proficient in Mandarin and knowledgeable in German.
Dr. Tina Xiang is a patent agent in the New York office of Wilson Sonsini Goodrich & Rosati. She has experience in the fields of cancer biology, targeted therapy, genetics, and cellular and molecular biology. Tina applies her experience to patent prosecution, freedom-to-operate, and due diligence matters for clients in the life sciences, pharmaceutical, biotechnology, diagnostics, and medical devices industries.
Prior to joining the firm, Tina completed her doctorate degree at Columbia University. Her dissertation focused on the development of subtype-specific targeted therapy for Muscle-Invasive Bladder Cancer. While at Columbia, Tina was also a fellow at Columbia Technology Ventures, the university’s technology transfer office.
Tina is proficient in Mandarin and knowledgeable in German.
- Ph.D., Pathobiology and Mechanisms of Disease, Columbia University, 2022
Recipient, NIDDK Endocrinology Training Grant
- B.S., Biology, University of North Carolina at Chapel Hill, 2017Double Minors in Chemistry and German, With Highest Distinction, Phi Beta Kappa
- U.S. Patent and Trademark Office
- Ph.D., Pathobiology and Mechanisms of Disease, Columbia University, 2022
Recipient, NIDDK Endocrinology Training Grant
- B.S., Biology, University of North Carolina at Chapel Hill, 2017Double Minors in Chemistry and German, With Highest Distinction, Phi Beta Kappa
- U.S. Patent and Trademark Office
Select Publications
- Co-author, “Development regeneration and tumorigenesis of the urothelium,” 149(9) Development, 2022
- Co-lead author, “Pparg signaling controls bladder cancer subtype and immune exclusion,” 12(1) Nat. commun 6160, 2021
- Co-author, “Pparg promotes differentiation and regulates mitochondrial gene expression in bladder epithelial cells,” 10(1) Nat. commun 4589, 2019
Select Publications
- Co-author, “Development regeneration and tumorigenesis of the urothelium,” 149(9) Development, 2022
- Co-lead author, “Pparg signaling controls bladder cancer subtype and immune exclusion,” 12(1) Nat. commun 6160, 2021
- Co-author, “Pparg promotes differentiation and regulates mitochondrial gene expression in bladder epithelial cells,” 10(1) Nat. commun 4589, 2019
Biological Sciences and Biotechnology
- Antibody
- Antigen presentation
- Cancer biology
- Cancer therapeutics
- CAR-T cells
- Cell biology
- Cell therapy
- Cellular immunology
- Epigenetics
- Genetics
- Immuno-oncology
- Molecular biology
- Molecular genetics
- Stem cell biology
Therapeutics and Drug Discovery
- Gene editing
- Gene therapy
- Immunotherapy targets
Biological Sciences and Biotechnology
- Antibody
- Antigen presentation
- Cancer biology
- Cancer therapeutics
- CAR-T cells
- Cell biology
- Cell therapy
- Cellular immunology
- Epigenetics
- Genetics
- Immuno-oncology
- Molecular biology
- Molecular genetics
- Stem cell biology
Therapeutics and Drug Discovery
- Gene editing
- Gene therapy
- Immunotherapy targets
The proceeds from the Series B will be used to advance the clinical development of Ona’s lead program, ONA-255, a first-in-class ADC initially focused on breast cancer, and to progress ONA-389, a second first-in-class ADC targeting colorectal cancer. ONA-255 is designed to address treatment-resistant tumor biology through a differentiated mechanism aimed at improving the therapeutic index compared to earlier approaches. ONA-389 will advance toward first-in-human studies, expanding Ona’s pipeline in indications with significant unmet need. Ona currently retains full worldwide commercial rights to all its assets.
- Privacy Policy
- Terms of Use
- Accessibility